Study Identifies 3 Key Trends Expected To Shape Health Benefits & Costs

Providing comprehensive health care benefits at an affordable cost is top of mind for nearly every employer in 2024. The latest Employee Health Trends report from the health intelligence platform Springbuk identified three key health issues that will affect how benefits leaders plan, deliver and evaluate employee benefits programs in the coming year.

“Our goal has been to equip employers and their benefits advisors with easy-to-use information to improve employee health, manage costs and understand program impact,” CEO Joy Powell said. “To accomplish this, our expert data scientists, clinicians and population health leaders dedicate significant amounts of time and resources to provide our community, customers and partners with these annual trend analyses that go beyond ‘what’ is driving costs in their population by delivering insight into the ‘why.’”

The wide-ranging report focused on three trends and how employers might respond:

Pharmacy spending. An increase of more than 1% in pharmacy spending is a major contributor to the overall 7% increase in employer-sponsored health insurance costs. A new study by the Business Group on Health reveals that amid increases in the percentage of health care dollars spent on pharmacy, 9 in 10 employers are concerned about high-cost drugs in the pipeline, with a similar number reporting concern about pharmacy cost trends overall.

“Ensure that strategies to address drug spending target both brand-name drugs and specialty drugs,” the report said. “The majority of drug spending is related to chronic conditions. Strategies aimed at the root causes of most chronic conditions, including diet, activity level, obesity and smoking, can result in reduced need for these drugs. Keep in mind that drugs that help members control their condition and prevent complications or progression can reduce other health care costs.”

High-cost claimants. These claimants are defined as individuals incurring $50,000 or more in total paid claims per year. From 2019 to 2023, the amount paid for the top 1% of high-cost claimants surged more than 15%, from $78,800 to $91,000. Further, one of every 1,000 plan members is likely to have total paid claims greater than $340,000.

“Understand the population at greatest risk of becoming a high-cost claimant based on conditions, history of being a high-cost claimant and demographic information,” the report said. “Consider whether the use of a clinical program partner addressing specific conditions or services would be cost-effective based on areas of greatest risk.”

GLP-1 weight-loss drugs. At a time when more than 4 in 10 Americans are considered clinically obese, GLP-1 drugs show great promise for weight loss. They also are prohibitively expensive, and not all insurance plans cover them.

“Management of obese members must consider any previous methods employed to achieve weight loss, subsequent outcomes and individual member risk,” the report said. “Typically, programs focused on diet, exercise and behavioral modifications should be tried first. Medications or bariatric surgery may be considered for members who are not able to achieve or sustain weight loss.”

 

Source Link

Recommended Articles

Schumer Announces Health Care Plan

Senate Minority Leader Chuck Schumer officially unveiled Democrats’ plan for a health care vote next week, saying Thursday on the chamber floor his caucus will propose extending soon-to-expire Affordable Care Act subsidies for three years. “This is the bill, a clean three-year extension of ACA tax credits, that Democrats will bring to the floor of ...

Read More

House Votes To Pass 5-Year Hospital At Home Extension, Sending Bill To The Senate

The House of Representatives unanimously voted to pass a bill Monday that extends the Medicare hospital at home program for five years. Hospital at home providers have been mired in uncertainty for years. Though Congress has repeatedly extended hospital at home flexibilities, it often only does so for a handful of months at a time. ...

Read More

Lobbyists Are Salivating For More Of Trump’s Drug Price Deals

Lobbyists for some of the world’s largest drug companies are parading a new pricing deal in the U.K. as a model the rest of Europe should emulate if it wants to keep drugmakers from bailing for America. To President Donald Trump and the lobbyists’ delight, British officials agreed to spend 25 percent more on new ...

Read More

Senate Barrels Toward Failure On Health Care

Senators have about a week before they’re set to vote on soon-to-expire Affordable Care Act subsidies. Most of them already believe the chances for a bipartisan breakthrough by then are roughly zero. There’s no clear momentum for any plan that would avoid a lapse in tax credits that could raise insurance premiums for 20 million ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square